| Pay vs Performance Disclosure - USD ($) | 12 Months Ended |
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
| Pay vs Performance Disclosure [Table] | | | |
| Pay vs Performance [Table Text Block] | Value of Initial Fixed $100 Investment Based on: Year Summary Compensation Table Total for PEO (1) Compensation Actually Paid to PEO (2) Average Summary Compensation Table Total for Non-PEO NEOs (3) Average Compensation Actually Paid to Non-PEO NEOs (3) Coherus Total Shareholder Return (TSR) (4) Peer Group TSR (5) Net Income (Loss) Net Product Revenue (Company-Selected Measure) (6) (a) (b)($) (c)($) (d)($) (e)($) (f)($) (g)($) (h)($ in 000's) (i)($ in 000's) 2022 6,866,396 212,826 2,122,124 470,265 (56) 11 (291,754) 210,760 2021 8,594,495 6,461,745 2,449,597 2,031,913 (11) 25 (287,100) 326,509 2020 7,278,761 8,381,980 2,035,344 2,408,072 (3) 26 132,244 475,824 (1) Represents total compensation paid to the principal executive officer, or PEO, Mr. Dennis Lanfear , as reflected in the Summary Compensation Table. (2) The following table sets forth the adjustments made during each year presented to arrive at CAP to our PEO during each year: 2022 2021 2020 ($) ($) ($) Summary Compensation Table (SCT) Total Compensation 6,866,396 8,594,495 7,278,761 Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT (5,071,908) (6,730,275) (5,454,150) Fair value as of year-end of equity awards granted during the year that remain unvested 1,795,132 3,351,633 3,953,739 Change in fair value of prior years' equity awards that remain unvested as of year-end (2,186,702) (576,558) 1,510,655 Fair value on vesting date for awards granted and vested in the same year 433,008 2,291,315 1,275,275 Change in fair value from prior year-end to vesting date of prior years' awards that vested during year (1,623,100) (468,865) (182,300) Compensation Actually Paid (CAP) 212,826 6,461,745 8,381,980 (3) The following table sets forth the adjustments made during each year presented to arrive at CAP to our non-PEO NEOs during each year: 2022 2021 2020 ($) ($) ($) Average SCT Total for Non-PEO NEOs 2,122,124 2,449,597 2,035,344 Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT (1,372,424) (1,829,098) (1,235,831) Fair value as of year-end of equity awards granted during the year that remain unvested 537,826 1,286,137 1,037,351 Change in fair value of prior years' equity awards that remain unvested as of year-end (550,147) (108,942) 439,657 Fair value on vesting date for awards granted and vested in the same year 86,062 294,903 159,400 Change in fair value from prior year-end to vesting date of prior years' awards that vested during year (353,176) (60,684) (27,849) Average CAP to Non-PEO NEOs 470,265 2,031,913 2,408,072 The non-PEO NEOs included in average compensation shown in columns (d) and (e) above are as follows: 2022 2021 2020 McDavid Stilwell Jean-Frederic Viret Jean-Frederic Viret Vladimir Vexler, Ph.D. McDavid Stilwell Vincent Anicetti Vincent Anicetti Vladimir Vexler, Ph.D. Vladimir Vexler, Ph.D. (4) Total Shareholder Return, or TSR, represents the cumulative growth of a hypothetical $100 investment in the Company made as of December 31, 2019, reflected as of the end of each respective year. (5) Peer group TSR represents the cumulative growth of a hypothetical $100 investment made as of December 31, 2019 in the Nasdaq Biotechnology Index, which we also use for purposes of the stock performance graph included in our Annual Report for the year ended December 31, 2022, reflected as of the end of each respective year. (6) SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (that is not TSR or net income) used by the Company to link the CAP of our NEOs, for the most recently completed fiscal year, to our performance. We selected Net Product Revenue as this measure for 2022 as reflected in column (i) in the first table above. Net product revenue is a Generally Accepted Accounting Principle measure reported in the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years. | | |
| Company Selected Measure Name | Net Product Revenue | | |
| Named Executive Officers, Footnote [Text Block] | (1) Represents total compensation paid to the principal executive officer, or PEO, Mr. Dennis Lanfear , as reflected in the Summary Compensation Table. The non-PEO NEOs included in average compensation shown in columns (d) and (e) above are as follows: 2022 2021 2020 McDavid Stilwell Jean-Frederic Viret Jean-Frederic Viret Vladimir Vexler, Ph.D. McDavid Stilwell Vincent Anicetti Vincent Anicetti Vladimir Vexler, Ph.D. Vladimir Vexler, Ph.D. | | |
| Peer Group Issuers, Footnote [Text Block] | (5) Peer group TSR represents the cumulative growth of a hypothetical $100 investment made as of December 31, 2019 in the Nasdaq Biotechnology Index, which we also use for purposes of the stock performance graph included in our Annual Report for the year ended December 31, 2022, reflected as of the end of each respective year. | | |
| PEO Total Compensation Amount | $ 6,866,396 | $ 8,594,495 | $ 7,278,761 |
| PEO Actually Paid Compensation Amount | $ 212,826 | 6,461,745 | 8,381,980 |
| Adjustment To PEO Compensation, Footnote [Text Block] | (2) The following table sets forth the adjustments made during each year presented to arrive at CAP to our PEO during each year: 2022 2021 2020 ($) ($) ($) Summary Compensation Table (SCT) Total Compensation 6,866,396 8,594,495 7,278,761 Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT (5,071,908) (6,730,275) (5,454,150) Fair value as of year-end of equity awards granted during the year that remain unvested 1,795,132 3,351,633 3,953,739 Change in fair value of prior years' equity awards that remain unvested as of year-end (2,186,702) (576,558) 1,510,655 Fair value on vesting date for awards granted and vested in the same year 433,008 2,291,315 1,275,275 Change in fair value from prior year-end to vesting date of prior years' awards that vested during year (1,623,100) (468,865) (182,300) Compensation Actually Paid (CAP) 212,826 6,461,745 8,381,980 | | |
| Non-PEO NEO Average Total Compensation Amount | $ 2,122,124 | 2,449,597 | 2,035,344 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 470,265 | 2,031,913 | 2,408,072 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (3) The following table sets forth the adjustments made during each year presented to arrive at CAP to our non-PEO NEOs during each year: 2022 2021 2020 ($) ($) ($) Average SCT Total for Non-PEO NEOs 2,122,124 2,449,597 2,035,344 Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT (1,372,424) (1,829,098) (1,235,831) Fair value as of year-end of equity awards granted during the year that remain unvested 537,826 1,286,137 1,037,351 Change in fair value of prior years' equity awards that remain unvested as of year-end (550,147) (108,942) 439,657 Fair value on vesting date for awards granted and vested in the same year 86,062 294,903 159,400 Change in fair value from prior year-end to vesting date of prior years' awards that vested during year (353,176) (60,684) (27,849) Average CAP to Non-PEO NEOs 470,265 2,031,913 2,408,072 | | |
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | | | |
| Compensation Actually Paid vs. Net Income [Text Block] | | | |
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | | | |
| Total Shareholder Return Vs Peer Group [Text Block] | | | |
| Tabular List [Table Text Block] | FINANCIAL PERFORMANCE MEASURE The following financial performance measure represents the most important financial measure used to link compensation actually paid to the NEOs for 2022 to Company performance: Net Product Revenue. | | |
| Total Shareholder Return Amount | $ (56) | (11) | (3) |
| Peer Group Total Shareholder Return Amount | 11 | 25 | 26 |
| Net Income (Loss) | $ (291,754,000) | $ (287,100,000) | $ 132,244,000 |
| Company Selected Measure Amount | 210,760,000 | 326,509,000 | 475,824,000 |
| PEO Name | Mr. Dennis Lanfear | | |
| Measure [Axis]: 1 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Net Product Revenue | | |
| Non-GAAP Measure Description [Text Block] | (6) SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (that is not TSR or net income) used by the Company to link the CAP of our NEOs, for the most recently completed fiscal year, to our performance. We selected Net Product Revenue as this measure for 2022 as reflected in column (i) in the first table above. Net product revenue is a Generally Accepted Accounting Principle measure reported in the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years. | | |
| PEO [Member] | Deduct for amounts reported under the "Stock Awards" and Option Awards" in the SCT | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | $ (5,071,908) | $ (6,730,275) | $ (5,454,150) |
| PEO [Member] | Fair value as of year-end of equity awards granted during the year that remain unvested | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 1,795,132 | 3,351,633 | 3,953,739 |
| PEO [Member] | Change in fair value of prior years' equity awards that remain unvested as of year-end | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (2,186,702) | (576,558) | 1,510,655 |
| PEO [Member] | Fair value on vesting date for awards granted and vested in the same year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 433,008 | 2,291,315 | 1,275,275 |
| PEO [Member] | Change in fair value from prior year-end to vesting date of prior years' awards that vested during year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (1,623,100) | (468,865) | (182,300) |
| Non-PEO NEO [Member] | Deduct for amounts reported under the "Stock Awards" and Option Awards" in the SCT | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (1,372,424) | (1,829,098) | (1,235,831) |
| Non-PEO NEO [Member] | Fair value as of year-end of equity awards granted during the year that remain unvested | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 537,826 | 1,286,137 | 1,037,351 |
| Non-PEO NEO [Member] | Change in fair value of prior years' equity awards that remain unvested as of year-end | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (550,147) | (108,942) | 439,657 |
| Non-PEO NEO [Member] | Fair value on vesting date for awards granted and vested in the same year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 86,062 | 294,903 | 159,400 |
| Non-PEO NEO [Member] | Change in fair value from prior year-end to vesting date of prior years' awards that vested during year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | $ (353,176) | $ (60,684) | $ (27,849) |
